検索結果 - Gozde Colak

Corporate Carbon Footprint Analysis: Example Calculation for a Chemical Factory 著者: Gözde Çolak, Burçin Atılgan Türkmen

全文の入手

Medicinal and Aromatic Plants of Esenli (Giresun) Forest Planning Unit 著者: Mustafa Karaköse, Gözde Çolak Karaköse

全文の入手

Complete transglutaminase 2 ablation results in reduced stroke volumes and astrocytes that exhibit increased survival in response to ischemia 著者: Gozde Colak, Gail V.W. Johnson

全文の入手

Cytosolic guanine nucledotide binding deficient form of transglutaminase 2 (R580a) potentiates cell death in oxygen glucose deprivation. 著者: Gozde Colak, Jeffrey W Keillor, Gail V W Johnson

全文の入手

P1018: UPDATED RESULTS FROM MANIFEST ARM 2: EFFICACY AND SAFETY OF PELABRESIB (CPI-0610) AS ADD-ON TO RUXOLITINIB IN MYELOFIBROSIS 著者: Marina Kremyanskaya, Claire Harrison, Prithviraj Bose, Vikas Gupta, Raajit K Rampal, Jonathan Lambert, Moshe Talpaz, Alessandro Vannucchi, Andrew Kuykendall, Jean-Jacques Kiladjian, Srdan Verstovsek, Ruben Mesa, Gozde Colak, Sandra Klein, Carmelita Alvero, John Mascarenhas

全文の入手

P1027: UPDATED DURABILITY OF RESPONSE AND SAFETY IN MANIFEST ARM 3: PELABRESIB (CPI-0610) COMBINED WITH RUXOLITINIB FOR JAK INHIBITOR TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS 著者: Claire Harrison, Andrea Patriarca, Vikas Gupta, Francesca Palandri, Timothy Devos, Raajit K Rampal, Moshe Talpaz, Alessandro Vannucchi, Andrew Kuykendall, Jean-Jacques Kiladjian, Srdan Verstovsek, Ruben Mesa, Gozde Colak, Soumik Dutta, Sandra Klein, Jie Cui, Tzuu-Wang Chang, John Mascarenhas

全文の入手

S168: PELABRESIB (CPI-0610) MONOTHERAPY IN PATIENTS WITH HIGH-RISK ESSENTIAL THROMBOCYTHEMIA REFRACTORY OR INTOLERANT TO HYDROXYUREA: PRELIMINARY RESULTS FROM MANIFEST STUDY 著者: Francesco Passamonti, Andrea Patriarca, Steven Knapper, Candido Rivera, Joseph M Scandura, Timothy Devos, Nikki Granacher, Adam Mead, Stephen Oh, Jeanne Palmer, Raajit K Rampal, Lino Teichmann, Qing LI, Jean-Pierre Eliane, Tzuu-Wang Chang, Sandra Klein, Gozde Colak, Claire Harrison

全文の入手